Pfizer’s Covid-19 Shot Offers 100% Long-Term Protection For Young Teens, Trial Shows

Pfizer and BioNTech said Monday that their vaccine offered long-term protection against Covid-19 in teenagers aged 12 to 15.
The Covid-19 vaccine provides 100% protection in teens.

The images are from the same source.

The effectiveness of the vaccine was measured from seven days to four months after the second shot.

The data from the late-stage clinical trial will be used to support submissions to the FDA and other global regulators for full regulatory approval in this age.
Pfizer said there were no serious safety concerns observed in the trial and the side effects were in line with other data reported for the vaccine.
The findings are important because of the rising rates of Covid-19 in this age group in some regions, according to Pfizer CEO Albert Bourla.
The Pfizer-BioNTech shot was approved for adolescents on an emergency basis in May. Children and teenagers have a lower chance of dying from Covid-19 than adults, but they can still develop life threatening illnesses and die from it, and officials and experts hailed the shot's emergency authorization as a way of tackling soaring infections and hospitalizations among children. Vaccination would make the return to school safer, though it introduced a complicating factor as to whether schools would mandate the shot. Most states have the power to require vaccinations for students at school, but few have begun to do so for Covid-19. The only state mandate for vaccination for K-12 students is contingent on FDA approval.
The number is big.

There were 9.9 million. More than half of 17 million teens who are eligible have already received at least one shot of the Pfizer-BioNTech vaccine, according to CDC data. Almost half of the people are fully vaccined.
There is a debate about whether vaccinating kids is the biggest problem.

Disney Cruise Requires Children 5 and Up to be fully Vaccined.

Coverage and live updates on the coronaviruses.

0 Comments

Post a comment

Your email address will not be published. Required fields are marked *

0 comments